Milos Holanek

5PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 25, 2025
Axillary Overtreatment in Patients with Breast Cancer After Neoadjuvant Chemotherapy in the Current Era of Targeted Axillary Dissection.

Ondřej Zapletal, Jan Žatecký, Lucie Gabrielová

|Jun 05, 2023
Level I axillary dissection in patients with breast cancer and tumor-involved sentinel lymph node after NAC is not sufficient for adequate nodal staging.

Jan Žatecký, Oldřich Coufal, Miloš Holánek

|Sep 23, 2022
Identification of AGR2 Gene-Specific Expression Patterns Associated with Epithelial-Mesenchymal Transition.

Andrea Martisova, Lucia Sommerova, Adam Krejci

|Jul 27, 2022
Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy.

Milos Holanek, Iveta Selingerova, Pavel Fabian

|Apr 03, 2021
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.

Milos Holanek, Iveta Selingerova, Ondrej Bilek

Pageof 1

Frequent Collaborators

4 joint publications

Iveta Selingerova

3 joint publications

Tomas Kazda

2 joint publications

Roman Hrstka

2 joint publications

Jan Žatecký